Alliance Pharma PLC Total Voting Rights (4091B)
01 Junio 2023 - 11:16AM
UK Regulatory
TIDMAPH
RNS Number : 4091B
Alliance Pharma PLC
01 June 2023
For immediate release 01 June 2023
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Total Voting Rights
Alliance Pharma plc (AIM: APH), the international healthcare
group, makes the following notification in accordance with the UK
Financial Conduct Authority's Disclosure and Transparency Rule
5.6.1.
As at 31 May 2023 the Company's issued share capital consists of
540,139,448 Ordinary Shares of 1p each.
The total number of voting rights in the Company is 540,139,448
and this figure may be used by shareholders as the denominator for
the calculations by which they should determine if they are
required to notify their interest in, or change to their interest
in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Cora McCallum, Head of Investor Relations
& Corporate Communications + 44 (0)1249 705168
ir@allianceph.com
+ 44 (0)20 7466
Buchanan 5000
Mark Court / Hannah Ratcliff
alliancepharma@buchanan.uk.com
Numis Securities Limited (Nominated Adviser + 44 (0)20 7260
and Corporate Broking) 1000
Freddie Barnfield / Duncan Monteith / Sher
Shah
+ 44 (0)20 7597
Investec Bank plc 5970
Corporate Broking: Patrick Robb
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare
company . Our purpose is to empower people to make a positive
difference to their health and wellbeing by making our trusted and
proven brands available around the world.
We deliver organic growth through investing in our priority
brands and channels, in related innovation, and through selective
geographic expansion to increase the reach of our brands.
Periodically, we may look to enhance our organic growth through
selective, complementary acquisitions .
Headquartered in the UK, the Group employs around 285 people
based in locations across Europe, North America, and the Asia
Pacific region. By outsourcing our manufacturing and logistics we
remain asset-light and focused on maximising the value we can
bring, both to our stakeholders and to our brands. For more
information on Alliance, please visit our website :
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRUPUPGQUPWGQG
(END) Dow Jones Newswires
June 01, 2023 12:16 ET (16:16 GMT)
Alliance Pharma (LSE:APH)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Alliance Pharma (LSE:APH)
Gráfica de Acción Histórica
De May 2023 a May 2024